Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 4/20 | 0.37 |
| ▸ | GSK3B | P49841 | 4/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | MGMT | P16455 | 1/20 | 0.36 |
| ▸ | PTAFR | P25105 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5339398 | 0.85 | ACP1 (0.39) | SMN1; SMN2GSK3AGSK3BCYP19A1CYP11B1 | |
| SCHEMBL5340881 | 0.84 | MAPT (0.37) | SMN1; SMN2CDK5CDK5R1CYP19A1CYP11B1 | |
| SCHEMBL4793392 | 0.83 | CDK5 (0.41) | SMN1; SMN2GSK3AGSK3BCDK5CDK5R1 | |
| SCHEMBL4766384 | 0.80 | CYP11B1 (0.38) | SMN1; SMN2CYP19A1CYP11B1CYP11B2POLB | |
| SCHEMBL4794120 | 0.80 | NCF1 (0.40) | SMN1; SMN2CYP19A1POLBMGMTCYP1A2 | |
| SCHEMBL6696621 | 0.78 | ACHE (0.42) | — | |
| SCHEMBL4766386 | 0.77 | CYP11B1 (0.38) | SMN1; SMN2CYP19A1CYP11B1CYP11B2POLB | |
| SCHEMBL2549528 | 0.75 | LMNA (0.52) | SMN1; SMN2POLBMAPT | |
| SCHEMBL562914 | 0.73 | CDK5 (0.48) | SMN1; SMN2CDK5CDK5R1POLBHTR6 | |
| SCHEMBL4775513 | 0.73 | LMNA (0.37) | SMN1; SMN2CYP19A1CYP11B1CYP11B2ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513524-A4 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2008-09-03 | — | — | EP | disclosed |
| US-7220758-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060252792-A1 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-11-09 | — | — | US | disclosed |
| US-7125890-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1513524-A2 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M Innovative Properties Company (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20050032830-A1 | Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors | 3M INNOVATIVE PROPERTIES COMPANY | 2005-02-10 | — | — | US | disclosed |
| US-6797718-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-28 | — | — | US | disclosed |
| US-20040010007-A1 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-15 | — | — | US | disclosed |
| WO-2003103584-A2 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252792-A1 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | IL2, IL4, MYD88 | SMN1; SMN2 2887/4885GSK3A 4805/4885GSK3B 4842/4885 |
| US-20050032830-A1 | Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors | IL2, IFNG, TSLP | SMN1; SMN2 4130/4885GSK3A 4632/4885GSK3B 4673/4885 |
| US-20040010007-A1 | Ether substituted imidazopyridines | IL2, IL4, MYD88 | SMN1; SMN2 2887/4885GSK3A 4805/4885GSK3B 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.